Jupiter Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Jupiter Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$464K	Hold	8,500	–	–	0.19%	69
2026 Q1	$448K	Hold	8,500	–	–	0.18%	69
2025 Q4	$416K	Hold	8,500	–	–	0.19%	62
2025 Q3	$551K	Buy	8,500 +1,000	+13%	+$57.4K	0.26%	60
2025 Q2	$430K	Hold	7,500	–	–	0.22%	63
2025 Q1	$290K	Hold	7,500	–	–	0.18%	59
2024 Q4	$295K	Hold	7,500	–	–	0.15%	76
2024 Q3	$352K	Hold	7,500	–	–	0.18%	71
2024 Q2	$430K	Hold	7,500	–	–	0.23%	66
2024 Q1	$400K	Hold	7,500	–	–	0.21%	66
2023 Q4	$470K	Hold	7,500	–	–	0.28%	64
2023 Q3	$399K	Hold	7,500	–	–	0.26%	61
2023 Q2	$421K	Hold	7,500	–	–	0.36%	50
2023 Q1	$339K	Hold	7,500	–	–	0.31%	47
2022 Q4	$304K	Hold	7,500	–	–	0.29%	45
2022 Q3	$490K	Hold	7,500	–	–	0.49%	41
2022 Q2	$455K	Hold	7,500	–	–	0.41%	44
2022 Q1	$470K	Hold	7,500	–	–	0.29%	61
2021 Q4	$568K	Sell	7,500 -4,000	-35%	-$349K	0.29%	57
2021 Q3	$1.01M	Sell	11,500 -1,000	-8%	-$126K	0.47%	49
2021 Q2	$1.71M	Hold	12,500	–	–	0.82%	35
2021 Q1	$1.65M	Sell	12,500 -500	-4%	-$75.5K	0.83%	33
2020 Q4	$1.99M	Hold	13,000	–	–	1.22%	26
2020 Q3	$1.09M	Sell	13,000 -4,551	-26%	-$404K	0.77%	33
2020 Q2	$1.67M	Hold	17,551	–	–	0.84%	32
2020 Q1	$851K	Buy	17,551 +35	+0.2%	+$1.81K	0.5%	35
2019 Q4	$1.04M	Sell	17,516 -26	-0.1%	-$1.42K	0.51%	36
2019 Q3	$719K	Sell	17,542 -30	-0.2%	-$1.43K	0.38%	41
2019 Q2	$865K	Buy	17,572 +151	+0.9%	+$6.04K	0.43%	39
2019 Q1	$632K	Buy	+17,421	New	+$602K	0.3%	44

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jupiter Wealth Management's CRSP Position: Q2 2026 in Review

Jupiter Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 8,500 shares worth $464K. The position accounts for 0.19% of the portfolio, ranked #69.

Jupiter Wealth Management first reported a position in CRSP in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.99M in Q4 2020. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Jupiter Wealth Management held 8,500 shares of CRISPR Therapeutics worth $464K as of Q2 2026.
Jupiter Wealth Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up 0.19% of Jupiter Wealth Management's portfolio in Q2 2026, its #69 holding.
Jupiter Wealth Management first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 30 quarters since.
Jupiter Wealth Management's CRISPR Therapeutics position peaked at $1.99M in Q4 2020.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Jupiter Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.